AMSBIO has added several new products to its range of genomic DNA and cDNA products derived from various human normal and disease state tissue types. These purified samples save valuable research time allowing the immediate identification of genes of interest without the need to acquire tissues and perform in-house processing. AMSBIO has added cancer and normal tissue cDNA arrays to its cDNA range which also includes individual PCR-ready first strand samples and panels. The cDNA in each array is synthesized from high quality total RNA from pathologically-verified tissues. Each array is provided with clinical information and QC data that has been both normalized and validated with ß-actin in two sequential qPCR analyses. These new arrays were developed for differential gene expression analysis and validation, enabling the study of hundreds of different human tissues in less than two hours. To aid the development of diagnostic tests and Next Generation Sequencing technology AMSBIO has introduced genomic DNA isolated from FFPE tissue and 96-well genomic DNA plates for high-throughput gene profiling studies in automated gene analysis systems.
AMSBIO LLC, 800-987-0985, www.amsbio.com